<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Pharmaceuticals</journal-id>
<journal-title>Pharmaceuticals</journal-title>
<issn pub-type="epub">1424-8247</issn>
<publisher>
<publisher-name>Molecular Diversity Preservation International (MDPI)</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3390/ph4030494</article-id>
<article-id pub-id-type="publisher-id">pharmaceuticals-04-00494</article-id>
<article-categories>
<subj-group>
<subject>Article</subject></subj-group></article-categories>
<title-group>
<article-title>RNA Detection in Live Bacterial Cells Using Fluorescent Protein Complementation Triggered by Interaction of Two RNA Aptamers with Two RNA-Binding Peptides</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Yiu</surname><given-names>Hung-Wei</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-04-00494"><sup>1</sup></xref><xref ref-type="fn" rid="fn1-pharmaceuticals-04-00494"><sup>†</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>Demidov</surname><given-names>Vadim V.</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-04-00494"><sup>1</sup></xref><xref ref-type="fn" rid="fn2-pharmaceuticals-04-00494"><sup>‡</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>Toran</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-04-00494"><sup>1</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>Cantor</surname><given-names>Charles R.</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-04-00494"><sup>1</sup></xref><xref ref-type="aff" rid="af2-pharmaceuticals-04-00494"><sup>2</sup></xref></contrib>
<contrib contrib-type="author">
<name><surname>Broude</surname><given-names>Natalia E.</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-04-00494"><sup>1</sup></xref><xref ref-type="corresp" rid="c1-pharmaceuticals-04-00494"><sup>*</sup></xref></contrib></contrib-group>
<aff id="af1-pharmaceuticals-04-00494">
<label>1</label> Program of Molecular and Cellular Biology and Biochemistry, Center for Advanced Biotechnology and Department of Biomedical Engineering, Boston University, 36 Cummington Street, Boston, MA 02215, USA</aff>
<aff id="af2-pharmaceuticals-04-00494">
<label>2</label> Sequenom, Inc., 3595 John Hopkins Court, San Diego, CA 92121, USA</aff>
<author-notes>
<corresp id="c1-pharmaceuticals-04-00494">
<label>*</label>Author to whom correspondence should be addressed: E-Mail: <email>nebroude@bu.edu</email>; Tel.: +1-617-358-4367; Fax: +1-617-353-8501.</corresp><fn id="fn1-pharmaceuticals-04-00494" fn-type="present-address">
<label>†</label>
<p>Current address: TaiDoc Technology, Wugu, Taipei 248, Taiwan.</p></fn><fn id="fn2-pharmaceuticals-04-00494" fn-type="present-address">
<label>‡</label>
<p>Current address: Global Prior Art, Inc., 21 Milk Street, Boston, MA 02109, USA.</p></fn></author-notes>
<pub-date pub-type="collection">
<year>2011</year></pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>03</month>
<year>2011</year></pub-date>
<volume>4</volume>
<issue>3</issue>
<fpage>494</fpage>
<lpage>508</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>12</month>
<year>2010</year></date>
<date date-type="rev-recd">
<day>17</day>
<month>01</month>
<year>2011</year></date>
<date date-type="accepted">
<day>11</day>
<month>02</month>
<year>2011</year></date></history>
<permissions>
<copyright-statement>© 2011 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
<copyright-year>2011</copyright-year>
<license>
<p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p></license></permissions>
<abstract>
<p>Many genetic and infectious diseases can be targeted at the RNA level as RNA is more accessible than DNA. We seek to develop new approaches for detection and tracking RNA in live cells, which is necessary for RNA-based diagnostics and therapy. We recently described a method for RNA visualization in live bacterial cells based on fluorescent protein complementation [<xref ref-type="bibr" rid="b1-pharmaceuticals-04-00494">1</xref>-<xref ref-type="bibr" rid="b3-pharmaceuticals-04-00494">3</xref>]. The RNA is tagged with an RNA aptamer that binds an RNA-binding protein with high affinity. This RNA-binding protein is expressed as two split fragments fused to the fragments of a split fluorescent protein. In the presence of RNA the fragments of the RNA-binding protein bind the aptamer and bring together the fragments of the fluorescent protein, which results in its re-assembly and fluorescence development [<xref ref-type="bibr" rid="b1-pharmaceuticals-04-00494">1</xref>-<xref ref-type="bibr" rid="b3-pharmaceuticals-04-00494">3</xref>]. Here we describe a new version of the RNA labeling method where fluorescent protein complementation is triggered by paired interactions of two different closely-positioned RNA aptamers with two different RNA-binding viral peptides. The new method, which has been developed in bacteria as a model system, uses a smaller ribonucleoprotein complementation complex, as compared with the method using split RNA-binding protein, and it can potentially be applied to a broad variety of RNA targets in both prokaryotic and eukaryotic cells. We also describe experiments exploring background fluorescence in these RNA detection systems and conditions that improve the signal-to-background ratio.</p></abstract>
<kwd-group>
<kwd>RNA aptamer</kwd>
<kwd>fluorescent protein</kwd>
<kwd>RNA-binding viral peptide</kwd>
<kwd>protein complementation</kwd>
<kwd>RNA localization</kwd>
<kwd><italic>E. coli</italic> cells</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<label>1.</label>
<title>Introduction</title>
<p>Recent advances in RNA studies <italic>in vivo</italic> mostly rely on fluorescent detection methods, where RNA-specific fluorescent probes are either delivered to cells (e.g., molecular beacons) or are synthesized inside the cell (e.g., the enhanced green fluorescent protein, EGFP, fused to an RNA-binding protein, e.g., MS2 coat protein or U1Ap RNA binding protein) [<xref ref-type="bibr" rid="b4-pharmaceuticals-04-00494">4</xref>,<xref ref-type="bibr" rid="b5-pharmaceuticals-04-00494">5</xref>]. Recently, an alternative system employing lambda N peptide-GFP fusion has been described [<xref ref-type="bibr" rid="b6-pharmaceuticals-04-00494">6</xref>] and used in combination with the MS2 labeling system to simultaneously label several RNAs [<xref ref-type="bibr" rid="b7-pharmaceuticals-04-00494">7</xref>]. Notwithstanding significant progress achieved in RNA studies using these methods, they all have certain limitations, and therefore new probes and methods for labeling RNA <italic>in vivo</italic> are in great demand.</p>
<p>Protein complementation (PC) and particularly fluorescent PC is widely used for protein-protein interaction studies both <italic>in vivo</italic> and <italic>in vitro</italic> due to several advantages over the competing techniques [<xref ref-type="bibr" rid="b4-pharmaceuticals-04-00494">4</xref>,<xref ref-type="bibr" rid="b8-pharmaceuticals-04-00494">8</xref>,<xref ref-type="bibr" rid="b9-pharmaceuticals-04-00494">9</xref>]. This method allows for lower background, since split fragments of the fluorescent protein are less fluorescent than the intact protein and reassemble into fully active proteins with the help of additional forces provided by the interacting molecules. Reassembly of the fluorescent protein takes place in a narrow set of conditions and with great dynamic range that results in high signal/background ratio [<xref ref-type="bibr" rid="b8-pharmaceuticals-04-00494">8</xref>]. These features of protein complementation make them perfect for both protein and nucleic acid studies [<xref ref-type="bibr" rid="b1-pharmaceuticals-04-00494">1</xref>-<xref ref-type="bibr" rid="b3-pharmaceuticals-04-00494">3</xref>,<xref ref-type="bibr" rid="b10-pharmaceuticals-04-00494">10</xref>-<xref ref-type="bibr" rid="b14-pharmaceuticals-04-00494">14</xref>].</p>
<p>Recently, we described a method for RNA visualization in live cells that uses a combination of fluorescent protein complementation and high affinity interaction of an RNA-binding protein with an aptamer [<xref ref-type="bibr" rid="b1-pharmaceuticals-04-00494">1</xref>-<xref ref-type="bibr" rid="b3-pharmaceuticals-04-00494">3</xref>]. In this method, the RNA-binding protein is the eukaryotic initiation factor 4A (eIF4A) which is a two-domain RNA helicase. This large protein (about 400 amino acid residues) is dissected into two fragments corresponding to the two domains, and each fragment is fused to the fragments of the split enhanced green fluorescent protein (EGFP). Co-expression of the two fusion proteins and a transcript tagged with an eIF4A-specific aptamer resulted in the fluorescent signal in bacteria which depended on the presence of RNA target. Importantly, LacZ mRNA and 5S ribosomal RNA displayed different localization patterns consistent with their functions [<xref ref-type="bibr" rid="b1-pharmaceuticals-04-00494">1</xref>]. This suggested that the protein labeling complex is not interfering with RNA localization and function. In a modified version of the eIF4A-based method with inducible RNA synthesis, we measured RNA kinetics in single cells and visualized RNA patterns suggesting non-random RNA distribution [<xref ref-type="bibr" rid="b3-pharmaceuticals-04-00494">3</xref>].</p>
<p>Here we present another approach to RNA visualization in live cells based on fluorescent protein complementation. Two different RNA aptamers are added as tags to the RNA molecule of interest; they bind with high affinity two RNA-binding peptides (∼20 amino acid residues) fused with the fragments of a split EGFP (<xref ref-type="fig" rid="f1-pharmaceuticals-04-00494">Figure 1</xref>).</p>
<p>There are several reasons for attempting these modifications. First, the ribonucleoprotein complex which is assembled on the target RNA is smaller as compared with that containing reassembled eIF4A protein. Smaller detection tools should provide lower probability of interference with function. Second, eIF4A protein is a component of the translation machinery in eukaryotic cells and it also has close homologs among bacterial proteins. Therefore, it cannot be excluded that its over-expression may interfere with essential biological functions in live cells. Short viral peptides on the other hand have no homologs in bacterial or in eukaryotic cells. Therefore their expression in a cell will less likely interfere with the cellular functions. Finally, an alternative design of the RNA recognizing complex adds more flexibility to the PC approach and expands the set of RNA-binding molecules applicable for RNA labeling methods.</p></sec>
<sec>
<label>2.</label>
<title>Experimental</title>
<sec>
<label>2.1.</label>
<title>Gel-Shift Assay of Peptide-RNA Aptamer Complexes Formed In Vitro</title>
<p>Custom-synthesized peptides, HTLV-1 Rex, HIV-1 Rev and bacteriophage λN, were purchased from GeneScript, (Piscataway, NJ) (<xref ref-type="table" rid="t1-pharmaceuticals-04-00494">Table 1</xref>). RNA aptamers as well as all DNA primers and templates were from IDT (Coralville, IA) (<xref ref-type="table" rid="t3-pharmaceuticals-04-00494">Table 1s</xref> of the Appendix). To assure correct folding of RNA aptamers, RNAs were first denatured by heating at 95 °C in buffer containing 50 mM Tris-HCl (pH 8.0), 50 mM KCl for 3 min and then slowly cooled to room temperature. Re-folded RNAs were mixed with increasing concentrations of the peptides in the same buffer and incubated at 30 °C for 15 min. Peptide-RNA aptamer complexes were analyzed by gel-shift assay using 15% polyacrylamige gel electrophoresis in Tris-Borate-EDTA buffer and then stained with ethidium bromide.</p></sec>
<sec>
<label>2.2.</label>
<title>Cloning and Expression of RNA Aptamers and Protein Fusions</title>
<p>The EGFP gene was split between amino acid residues 158 and 159 into two fragments, termed α-EGFP (N-terminal fragment) and β-EGFP (C-terminal fragment), respectively. A multi-step PCR was performed to create a DNA fragment that encodes two fusion proteins, HTLV-1 Rex peptide-α-EGFP and bacteriophage λN peptide-β-EGFP, plus T7 promoter in between (the resulting plasmid and the detailed PCR scheme are shown in <xref ref-type="fig" rid="f6-pharmaceuticals-04-00494">Figures 1s</xref> and <xref ref-type="fig" rid="f7-pharmaceuticals-04-00494">2s</xref> of the Appendix). HTLV-1 Rex peptide was fused to the C-terminus of the α-EGFP via a flexible 10-mer oligopeptide linker (Gly-Ser-Ser-Gly-Ser-Ser-Gly-Ser-Gly-Ser); bacteriophage λN peptide was fused to the N-terminus of the β-EGFP via the same 10-mer linker. The DNA construct was inserted into the pACYCDuet-1 vector (Novagen) between the restriction sites <italic>NcoI</italic> and <italic>Avr</italic>II, which placed the insert after the first T7 promoter region and before the T7 terminator region (<xref ref-type="fig" rid="f6-pharmaceuticals-04-00494">Figure 1s</xref>). All constructs were verified by sequencing. Thus, two fusion proteins were expressed from the two-cystronic pACYCDuet-1 plasmid to ensure similar amounts of both proteins. Expression of both fusion proteins was verified by protein gel electrophoresis.</p>
<p>To clone aptamers, a DNA sequence was designed which encodes two RNA aptamers, one of which binds the λN peptide and the other the HTLV-1 Rex peptide. The aptamer sequences were separated by a dT<sub>10</sub> linker, and the restriction sites for <italic>Xba</italic>I and <italic>Avr</italic>II were added at the ends. Custom synthesized DNA template was PCR-amplified, inserted between the <italic>Xba</italic>I and <italic>Avr</italic>II restriction sites in the pETDuet-1 vector (Novagen) under the control of the T7/<italic>LacO</italic> promoter, and cloned in <italic>E. coli</italic> strain BL21 (DE3). As a result, RNA was transcribed from this plasmid as a short untranslated transcript without a ribosome binding site and containing two adjacent aptamers separated by 10Ts. As a negative control, DNA sequence encoding two identical RNA aptamer sequences binding HTLV-1 Rex peptides was synthesized and similarly cloned into pETDuet-1 vector. DNA templates and primers are listed in <xref ref-type="table" rid="t3-pharmaceuticals-04-00494">Tables 1s</xref> and <xref ref-type="table" rid="t4-pharmaceuticals-04-00494">2s</xref> of the Appendix.</p></sec>
<sec>
<label>2.3.</label>
<title>Cell Growth Conditions and Induction</title>
<p>Two plasmids encoding protein and RNA components of the complementation complexes were co-expressed in <italic>E. coli</italic> BL21 (DE) 3 <italic>(B F<sup>−</sup> dcm ompT hsdS (r<sub>B</sub><sup>−</sup> m<sub>B</sub><sup>−</sup>) gal λ</italic> (DE3)) (Stratagene). As a negative control, the cells were transformed with a plasmid expressing two identical aptamers. Single colonies of transformed cells were grown first at 37 °C in LB medium supplemented with antibiotics for 3 h. Then, cultures were diluted 300-fold into fresh LB medium containing the inducer isopropyl-β-D-thiogalactopyranoside (IPTG) and grown overnight at room temperature. Optical density of the cultures (OD<sub>600</sub>) was between 0.4 and 0.6 at the time of examination.</p></sec>
<sec>
<label>2.4.</label>
<title>Flow Cytometry</title>
<p>Fluorescence measurements were obtained with a Becton-Dickinson FACSCalibur flow cytometer with a 488-nm argon excitation laser and a 515–545 nm emission filter (FL1). 500 μL of the cells induced overnight (OD<sub>600</sub> = 0.4 to 0.6) were washed once with PBS buffer prior to assaying. In total 100,000 cells have been analyzed.</p></sec>
<sec>
<label>2.5.</label>
<title>Fluorescence Microscopy, Imaging and Data Analysis</title>
<p>Induced bacterial cells in culture were immobilized between a cover slip and a thin slab of 0.8% agarose in 1X PBS. Time-lapse fluorescence microscopy was performed at room temperature with a Nikon Eclipse 80i inverted microscope equipped with an epifluorescence system X-Cite 120. Images were taken with exposure times of 150–300 ms using a digital black and white camera (12 bit; 20 mHz) with 100x magnification objective controlled by IPLab v.3.7 software (Scanalytics, Inc). An ND4 filter was used to reduce cell photo-damage. Pseudo-green color was added according to the fluorescence level in the florescent images. Image processing was performed using ImageJ 1.36 B software (Wayne Rasband, NIH).</p></sec></sec>
<sec sec-type="results|discussion">
<label>3.</label>
<title>Results and Discussion</title>
<sec>
<label>3.1.</label>
<title>Design of a Protein Complementation Complex for RNA Detection Based on Interaction of the Two RNA Aptamers with Two RNA-Binding Viral Peptides</title>
<p>To detect RNA in live bacterial cells we tagged it with two different RNA aptamer sequences which bind two different viral peptides with high affinity. Each peptide was expressed in the cell as a fusion with one of the two fragments of a split enhanced green fluorescent protein (EGFP) (<xref ref-type="fig" rid="f1-pharmaceuticals-04-00494">Figure 1</xref>). Interaction of each peptide with its cognate aptamer should bring together the two fragments of split EGFP. High local concentrations of the split fragments of EGFP will result in their re-association and development of the fluorescent signal. This approach is a further elaboration of a PC method used by Rackam and Brown to study RNA/protein interactions [<xref ref-type="bibr" rid="b14-pharmaceuticals-04-00494">14</xref>]. In this study, an MS2 binding motif was artificially introduced into RNA, while the second RNA/protein contact was probed by PC. To do so the authors expressed MS2 protein and RNA-binding proteins (FMRP or IMP1) as fusions with the split fluorescent proteins. In other words in this study one aptamer was introduced into RNA, while the other site was an endogenous RNA site which interaction with the RNA-binding protein was in question [<xref ref-type="bibr" rid="b14-pharmaceuticals-04-00494">14</xref>].</p>
<p>To develop an efficient PC method based on two aptamers/two peptides interactions, several issues should be considered. The affinity of each interacting peptide/aptamer pair should be high enough (in the nanomolar range) and ideally it should be comparable for both pairs. There should be no cross-reactivity between the two peptide/aptamer pairs. Also, there should be no interaction between the RNA-binding peptides in absence of RNA, which could otherwise bring the fragments of a detector protein together and thus increase the non-specific background. The RNA-binding peptides should be of comparable length to avoid distorting the assembly of the protein complementation complex. Finally, the placement of the two RNA aptamers on the target RNA should allow accessibility of the corresponding RNA-binding peptides to the cognate RNA aptamers. This implies that a flexible linker of sufficient length should be placed between the RNA aptamer tags.</p>
<p>It is known that the high-affinity and high-specificity interactions of many RNA-binding proteins with the corresponding RNAs are determined by the peptide sequences which contain arginine-rich motifs (ARMs) [<xref ref-type="bibr" rid="b15-pharmaceuticals-04-00494">15</xref>]. Recent studies aimed to understand the mechanism of ARM peptides interaction with the corresponding RNAs concluded that specific binding is determined by a particular pattern of arginines in the peptide and flexibility of the peptide backbone [<xref ref-type="bibr" rid="b16-pharmaceuticals-04-00494">16</xref>]. However, many ARM peptides display a promiscuous behavior by binding several different RNA targets, although with lesser affinity [<xref ref-type="bibr" rid="b17-pharmaceuticals-04-00494">17</xref>]. Keeping all this in mind, we chose three RNA-binding peptides from viral ARM peptides [<xref ref-type="bibr" rid="b18-pharmaceuticals-04-00494">18</xref>-<xref ref-type="bibr" rid="b20-pharmaceuticals-04-00494">20</xref>], and first tested their cross-reactivity with the corresponding RNAs before employing them in our protein complementation system.</p></sec>
<sec>
<label>3.2.</label>
<title><italic>In Vitro</italic> Testing of Cross-Reactivity of RNA Aptamer-Peptide Pairs</title>
<p>In these <italic>in vitro</italic> experiments the increasing concentrations of the ARM peptides were combined with RNA aptamers at fixed concentrations. The complexes were then qualitatively analyzed by a non-radioactive gel-shift assay (see <xref ref-type="fig" rid="f2-pharmaceuticals-04-00494">Figure 2</xref> for the exemplary gel picture). The results showed that the bacteriophage λN peptide and HTLV-1 Rex peptide bind their corresponding RNA aptamers in the nanomolar concentration range and did not display cross-reactivity with the non-cognate aptamers. At the same time, HIV-1 Rev peptide did show some cross-reactivity with the two non-matched aptamers (<xref ref-type="fig" rid="f2-pharmaceuticals-04-00494">Figure 2</xref> and <xref ref-type="table" rid="t2-pharmaceuticals-04-00494">Table 2</xref>). Based on these results, we concluded that the bacteriophage λN and HTLV-1 Rex peptides along with their corresponding RNA aptamers can be used in the PC-based RNA detection method.</p></sec>
<sec>
<label>3.3.</label>
<title>Optimization of Detection of RNA Transcripts in Live Bacterial Cells Using Binary Peptide/Aptamer Interactions</title>
<p>The C-terminus of the EGFP fragment (1–158 aa) was fused to the N-terminus of the HTLV-1 Rex peptide (16 aa-long) via a flexible linker consisting of serine and glycine residues [<xref ref-type="bibr" rid="b21-pharmaceuticals-04-00494">21</xref>,<xref ref-type="bibr" rid="b22-pharmaceuticals-04-00494">22</xref>]. We used the same GS-rich linkers that we used earlier in our eIF4A-based complementation system [<xref ref-type="bibr" rid="b1-pharmaceuticals-04-00494">1</xref>-<xref ref-type="bibr" rid="b3-pharmaceuticals-04-00494">3</xref>]. Similarly, the N-terminus of the second EGFP fragment (159–238 aa) was fused to the C-terminus of λN peptide (22 aa) via the same polypeptide linker. The vector pETDuet-1 (Novagen) was used for the expression of an untranslated T7-transcript containing two aptamer sequences linked by the T<sub>10</sub> sequence. Preliminary experiments with T<sub>5</sub> and T<sub>10</sub> linkers did not show substantial difference. Therefore, we used the constructs with T<sub>10</sub> linkers through out this study.</p>
<p><italic>E. coli</italic> cells expressing the entire complementation complex and appropriate controls were grown overnight at room temperature in the presence of the inducer, isopropyl-ß-D-thiogalactopyranoside (IPTG) for co-expression of proteins and RNA. Fluorescence of these cells was compared with fluorescence of the cells expressing two protein fusions in RNA absence and cells expressing two protein fusions plus an incorrect combination of the two aptamers (two HTLV-1 Rex peptide-binding aptamers linked with the T<sub>10</sub>-linker).</p>
<p>Our experiments with the complementing fusion proteins containing short viral peptides, as well as the fragments of the split eIF4A protein, revealed that background fluorescence caused by spurious self-assembly of the protein fragments can be modulated by cell growth conditions and IPTG concentration (<xref ref-type="fig" rid="f3-pharmaceuticals-04-00494">Figure 3</xref>). These two parameters, the temperature and IPTG concentration, have an effect on the split protein concentrations by two different mechanisms. Low IPTG concentrations decrease the overall concentration of split proteins, and thus effectively lower the incidence of their spurious re-assembly. The temperature of overnight culture incubation also has a large effect on cell fluorescence by affecting the concentration of properly folded split proteins. At lower temperature, the amount of properly folded and functional proteins synthesized is higher than at higher temperature. Therefore, at 20 °C a high incidence of spurious re-assembly results in a higher background signal than at 30 °C (∼100–200 a. u. versus 20–40 a. u.), in the system based on the eIF4A protein (<xref ref-type="fig" rid="f3-pharmaceuticals-04-00494">Figure 3A</xref>). It should be emphasized that this background is two orders of magnitude lower than in the cells expressing native EGFP (<xref ref-type="fig" rid="f3-pharmaceuticals-04-00494">Figure 3</xref>). The cells expressing fusions of the split EGFP with the viral peptides usually displayed higher background than the cells expressing split eIF4A fusion proteins (compare <xref ref-type="fig" rid="f3-pharmaceuticals-04-00494">Figures 3A and 3B</xref>). This can probably be explained by the positive charges of these arginine-rich peptides that non-specifically bind to the negatively charged molecules or surfaces. To overcome this non-specific background in the cells expressing fusion proteins with the viral peptides we changed the second parameter affecting signal-to-background ratio: we varied concentrations of the inducer, IPTG.</p>
<p>An example of signal-to-background optimization experiments with the protein complementation system using viral peptides is shown in <xref ref-type="fig" rid="f4-pharmaceuticals-04-00494">Figure 4</xref>. At 25 °C <italic>E. coli</italic> cells expressing two fusion proteins induced with 1 mM IPTG displayed high fluorescence in the absence of RNA target, and there was also no difference in fluorescence distribution in the cells expressing correct or incorrect aptamer sequences (<xref ref-type="fig" rid="f4-pharmaceuticals-04-00494">Figure 4</xref>). Decreasing the concentration of IPTG 10-fold resulted in separation of the fluorescence distributions for the cells expressing only fusion proteins and those expressing fusion proteins and RNA aptamers (<xref ref-type="fig" rid="f4-pharmaceuticals-04-00494">Figure 4</xref>). By decreasing the concentration of IPTG to 0.01 mM it was possible to resolve the cognate aptamer-dependent fluorescence from that of the targets with incorrect aptamer sequences (<xref ref-type="fig" rid="f4-pharmaceuticals-04-00494">Figure 4</xref>). Under optimized conditions, the average fluorescence of the cells expressing the entire complementation complex exceeded background fluorescence (no RNA component) 10–15 fold, and cells with correct RNA-tagging aptamer sequences displayed 4–5 times higher fluorescence than cells with the non-matched RNA tags (<xref ref-type="fig" rid="f4-pharmaceuticals-04-00494">Figures 4</xref> and <xref ref-type="fig" rid="f5-pharmaceuticals-04-00494">5</xref>).</p>
<p>Bacterial cells expressing a short untranslated RNA tagged with the two aptamers at optimized conditions were analyzed using fluorescent microscopy. In most cells bright fluorescent spots were seen at the cell poles (<xref ref-type="fig" rid="f5-pharmaceuticals-04-00494">Figure 5F</xref>) similar to the results obtained in the experiments when an untranslated transcript was labeled by PC triggered by eIF4A-aptamer interactions [<xref ref-type="bibr" rid="b1-pharmaceuticals-04-00494">1</xref>] (<xref ref-type="fig" rid="f5-pharmaceuticals-04-00494">Figure 5E</xref>).</p></sec></sec>
<sec sec-type="conclusions">
<label>4.</label>
<title>Conclusions</title>
<p>In this study we aimed at development of an alternative to eIF4A protein-based fluorescent complementation system which would widen the choice of molecules for RNA labeling in live cells. The results show that the RNA detection system based on binary interactions of two RNA aptamers with short viral peptides presents an attractive alternative to the system based on the split eIF4A protein. It uses smaller protein complementation complex consisting of short viral peptides which are less likely to interfere with bacterial or eukaryotic cell metabolism. We have shown that under optimized conditions when the two viral peptides recognize two correct RNA aptamers the mean fluorescence of the cells exceeds negative controls 3–4 fold, as it was the case with the eIF4A-based system [<xref ref-type="bibr" rid="b1-pharmaceuticals-04-00494">1</xref>].</p>
<p>The experiments exploring background fluorescence showed that in both protein complementation systems (using split eIF4A or two short viral peptides) the source of background fluorescence is the same and it can be modulated by changing conditions of cell growth, specifically by concentrations of the inducer, IPTG, and by changing the temperature of cell culturing. The slightly higher background in the PC system using viral peptides can be likely explained by the aggregation of the arginine-rich peptides. However, it does not change the major trend characteristic to both PC systems (compare the results in <xref ref-type="fig" rid="f3-pharmaceuticals-04-00494">Figures 3A and 3B</xref>). We should also emphasize that the presented results are important not only for the RNA PC-based studies, but for all methods using fluorescent PC.</p></sec></body>
<back>
<sec sec-type="display-objects">
<title>Figures and Tables</title>
<fig id="f1-pharmaceuticals-04-00494" position="float">
<label>Figure 1.</label>
<caption>
<p>Fluorescent protein complementation based on binary peptide-RNA aptamer interactions. Two fragments of EGFP, α- and β-, are fused with the two viral peptides, HIV-1 Rex peptide and bacteriophage λN peptide. In the presence of an RNA transcript bearing two corresponding aptamers, the two peptides interact with their cognate aptamers and bring together two fragments of split EGFP. Re-assembly of EGFP results in fluorescent signal.</p></caption>
<graphic xlink:href="pharmaceuticals-04-00494f1.gif"/></fig>
<fig id="f2-pharmaceuticals-04-00494" position="float">
<label>Figure 2.</label>
<caption>
<p>Cross-reactivity of three pairs of peptide/RNA aptamers. In these titration experiments, the variable amounts of viral peptides were in excess over fixed amounts of RNA aptamers (∼20 nmole).</p></caption>
<graphic xlink:href="pharmaceuticals-04-00494f2.gif"/></fig>
<fig id="f3-pharmaceuticals-04-00494" position="float">
<label>Figure 3.</label>
<caption>
<p>Background fluorescence in <italic>E. coli</italic> cells expressing protein fusions can be regulated by the temperature of cell culturing. (<bold>A</bold>). <italic>E. coli</italic> MB61 cells express two fusion proteins α-F1 and β-F2, fragments of EGFP and eIF4A proteins. Two fusion proteins were cloned in the vector pACYCDuet 1 and induced with 1 mM IPTG at different temperatures. Fluorescence of the <italic>E. coli</italic> cells BL21(DE3) and the cells expressing intact EGFP from the same vector is shown for comparison; (<bold>B</bold>). Rex/Lambda N denote <italic>E. coli</italic> cells which express two fusion proteins containing fragments of split EGFP fused to HTLV-1 Rex and lambda N peptides. The protein fusions were cloned into the plasmid pACYCDuet 1 and induced with 1 mM IPTG at different temperatures. Fluorescence of the <italic>E. coli</italic> cells BL21(DE3) and the cells expressing intact EGFP is shown for comparison.</p></caption>
<graphic xlink:href="pharmaceuticals-04-00494f3.gif"/></fig>
<fig id="f4-pharmaceuticals-04-00494" position="float">
<label>Figure 4.</label>
<caption>
<p>Low concentration of IPTG allows discrimination of signal from the background using binary aptamer/peptide interactions. Blue, fluorescence distributions of the cells expressing two fusion proteins in RNA absence; red, fluorescence distribution of the cells expressing two fusion proteins and RNA aptamers with the wrong sequences (two HTLV-1 Rex aptamers); black, fluorescence distribution of the <italic>E. coli</italic> cells expressing two fusion proteins and RNA with two cognate aptamers.</p></caption>
<graphic xlink:href="pharmaceuticals-04-00494f4.gif"/></fig>
<fig id="f5-pharmaceuticals-04-00494" position="float">
<label>Figure 5.</label>
<caption>
<p>Fluorescent images of <italic>E. coli</italic> cells expressing RNA transcript tagged with the two aptamers. (<bold>A</bold>). FACS analysis of the <italic>E. coli</italic> cells: Blue, the cells express two fusion proteins in RNA absence; red, the cells express two fusion proteins and RNA aptamers with the wrong sequences (two HTLV-1 Rex aptamers); black, <italic>E. coli</italic> cells express two fusion proteins and RNA with two cognate aptamers; (<bold>B</bold>). Fluorescent microscopy: The control cells express fusion proteins in RNA absence; (<bold>C</bold>). the control cells express RNA with one non-cognate aptamer and fusion proteins; (<bold>D</bold>). the cells express fusion proteins and a transcript with two cognate aptamers. Scale bar, 5 μm; all images were taken under similar conditions; (<bold>E</bold>). Fluorescence distributions in single <italic>E. coli</italic> cells expressing reporter RNA and labeled using eIF4A system [<xref ref-type="bibr" rid="b1-pharmaceuticals-04-00494">1</xref>]; (<bold>F</bold>). Fluorescence distributions in single <italic>E. coli</italic> cells expressing reporter RNA and labeled using binary viral peptide/aptamer system.</p></caption>
<graphic xlink:href="pharmaceuticals-04-00494f5.gif"/></fig>
<table-wrap id="t1-pharmaceuticals-04-00494" position="float">
<label>Table 1.</label>
<caption>
<p>Peptide and RNA aptamer sequences used in this study.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom"><bold>Peptide/aptamer pair</bold></th>
<th align="left" valign="bottom"><bold>Bacteriophage λN/aptamer pair</bold></th>
<th align="left" valign="bottom"><bold>HTLV-1 Rex/aptamer pair</bold></th>
<th align="left" valign="bottom"><bold>HIV-1 Rev/aptamer pair</bold></th></tr></thead>
<tbody>
<tr>
<td align="left" valign="middle">RNA aptamer sequence in MFOLD format</td>
<td align="left" valign="middle">
<graphic xlink:href="pharmaceuticals-04-00494t1.gif"/></td>
<td align="left" valign="middle">
<graphic xlink:href="pharmaceuticals-04-00494t2.gif"/></td>
<td align="left" valign="middle">
<graphic xlink:href="pharmaceuticals-04-00494t3.gif"/></td></tr>
<tr>
<td align="left" valign="middle">Peptide sequence</td>
<td align="left" valign="middle">MDAQTRRRERRAEKQAQWKAAN</td>
<td align="left" valign="middle">MPKTRRRPRRSQRKRP</td>
<td align="left" valign="middle">TRQARRNRRRRWRERQR</td></tr>
<tr>
<td align="center" valign="middle">Reference</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="b20-pharmaceuticals-04-00494">20</xref>]</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="b18-pharmaceuticals-04-00494">18</xref>]</td>
<td align="center" valign="middle">[<xref ref-type="bibr" rid="b19-pharmaceuticals-04-00494">19</xref>]</td></tr></tbody></table></table-wrap>
<table-wrap id="t2-pharmaceuticals-04-00494" position="float">
<label>Table 2.</label>
<caption>
<p>Cross-reactivity between three RNA aptamer/peptide pairs. (++, strong interaction; +, cross-reactivity; −, lack of interaction).</p></caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="right" valign="middle"><bold>RNA aptamer</bold></th>
<th align="center" valign="middle" rowspan="2"><bold>HTLV-1 Rex</bold></th>
<th align="center" valign="middle" rowspan="2"><bold>λN</bold></th>
<th align="center" valign="middle" rowspan="2"><bold>HIV-1 Rev</bold></th></tr>
<tr>
<th align="left" valign="middle"><bold>Peptide</bold></th></tr></thead>
<tbody>
<tr>
<td align="center" valign="top">HTLV-1 Rex peptide <xref ref-type="table-fn" rid="tfn1-pharmaceuticals-04-00494">*</xref></td>
<td align="center" valign="top">++</td>
<td align="center" valign="top">−</td>
<td align="center" valign="top">−</td></tr>
<tr>
<td align="center" valign="top">Bacteriophage λN peptide</td>
<td align="center" valign="top">−</td>
<td align="center" valign="top">++</td>
<td align="center" valign="top">−</td></tr>
<tr>
<td align="center" valign="top">HIV-1 Rev peptide</td>
<td align="center" valign="top">+</td>
<td align="center" valign="top">+</td>
<td align="center" valign="top">++</td></tr></tbody></table>
<table-wrap-foot><fn id="tfn1-pharmaceuticals-04-00494">
<label>*</label>
<p>50% binding of HTLV-1 Rex peptide to HTLV-1 Rex aptamer was observed at a concentration of peptide ∼300 nM, when this peptide was in excess over RNA.</p></fn></table-wrap-foot></table-wrap></sec>
<ack>
<p>This work was sponsored by Hamilton Thorne Biosciences and supported in part by a SPRiNG award (Boston University) and DiThera Inc. to N.E.B.</p></ack>
<app-group>
<app>
<title>Appendix</title>
<fig id="f6-pharmaceuticals-04-00494" position="anchor">
<label>Figure 1s.</label>
<caption>
<p>The plasmid expressing two fusion proteins. (<bold>A</bold>). Plasmid structure; (<bold>B</bold>). DNA fragment that was created by multi-step PCR (see <xref ref-type="fig" rid="f7-pharmaceuticals-04-00494">Figure 2s</xref>) and inserted into vector pACYCDuet-1 between NcoI /AvrII sites.</p></caption>
<graphic xlink:href="pharmaceuticals-04-00494f6.gif"/></fig>
<fig id="f7-pharmaceuticals-04-00494" position="anchor">
<label>Figure 2s.</label>
<caption>
<p>Multi-step PCR used to obtain DNA fragment encoding the two fusion proteins and all regulatory regions Each pair of PCR products to be joined has about 10 bp of sequence overlap. Pairs were mixed and used as a template for the next PCR reaction. The plasmid containing EGFP gene (from Clonetech) was used as a template for PCR products (1) and (4). Templates for PCR products (2), (3) and (6) were custom synthesized. After PCR 1, PCR products (1) and (2) were mixed and used as a template for amplifying PCR product (5). PCR products (3) and (4) were mixed and used as a template for amplifying PCR product (7). After PCR 2 amplification, PCR products (6) and (7) were mixed as a template for amplifying PCR product (8). The last PCR 4 was carried out by mixing PCR products (5) and (8) as a template. Final PCR product (9) was inserted into pACYCDuet-1 vector. Sequences of DNA templates and primers are listed in <xref ref-type="table" rid="t3-pharmaceuticals-04-00494">Table 1s</xref> and <xref ref-type="table" rid="t4-pharmaceuticals-04-00494">Table 2s</xref>.</p></caption>
<graphic xlink:href="pharmaceuticals-04-00494f7.gif"/></fig>
<table-wrap id="t3-pharmaceuticals-04-00494" position="anchor">
<label>Table 1s.</label>
<caption>
<p>DNA templates used in this study for PCR amplifications.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle"><bold>Template Encode</bold></th>
<th align="left" valign="middle"><bold>Sequence (5′ to 3′)</bold></th></tr></thead>
<tbody>
<tr>
<td align="left" valign="top">Linker + Rex peptide</td>
<td align="left" valign="top">GGATCCTCTGGATCTTCGGGTTCTGGTAGCATGCCCAAGACCCGT CGGAGGCCCCGCCGATCCCAAAGAAAAAGACCA</td></tr>
<tr>
<td align="left" valign="top">λN peptide + linker</td>
<td align="left" valign="top">ATGGATGCACAAACACGCCGCCGCGAACGTCGCGCAGAGAAACAGGCTCAATGGAAAGCAGCAAATGGATCCTCTGGATCTTCGGGTTCTGGT AGC</td></tr>
<tr>
<td align="left" valign="top">Rex and λN aptamers + linker</td>
<td align="left" valign="top">CACCAGGCCACGAGTCTAGAGGATCCGGGCCCTGAAGAAGGGCCCTTTCCTTTTTTTTTTTTTTAGGCGACGGTACGCAAGTACTCTTGCGCCGGCCTACCTAGGGACGAGCAGCAGGC</td></tr>
<tr>
<td align="left" valign="top">2 Rex aptamers + linker</td>
<td align="left" valign="top">CACCAGGCCACGAGTCTAGATAGGCGACGGTACGCAAGTACTCTTGCGCCGGCCTATTTTTTTTTTTAGGCGACGGTACGCAAGTACTCTTGCGCCGGCCTACCTAGGGACGAGCAGCAGGC</td></tr></tbody></table></table-wrap>
<table-wrap id="t4-pharmaceuticals-04-00494" position="anchor">
<label>Table 2s.</label>
<caption>
<p>Primers used for PCR amplification (see <xref ref-type="fig" rid="f7-pharmaceuticals-04-00494">Figure 2s</xref>).</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom"><bold>Primer</bold></th>
<th align="left" valign="bottom"><bold>Sequence (5′ to 3′)</bold></th>
<th align="left" valign="bottom"><bold>Note</bold></th></tr></thead>
<tbody>
<tr>
<td align="left" valign="middle">P1UP</td>
<td align="left" valign="middle">ATA ACC CAT GGT GAG CAA GGG C</td>
<td align="left" valign="middle">Upstream primer for PCR products (1)(5)</td></tr>
<tr>
<td align="left" valign="middle">P1DN</td>
<td align="left" valign="middle">CAG AGG ATC CCT GCT TGT CGG CC</td>
<td align="left" valign="middle">Downstream primer for PCR product (1)</td></tr>
<tr>
<td align="left" valign="middle">P2UP</td>
<td align="left" valign="middle">CGA CAA GCA GGG ATC CTC TGG ATC T</td>
<td align="left" valign="middle">Upstream primer for PCR product (2)</td></tr>
<tr>
<td align="left" valign="middle">P2DN</td>
<td align="left" valign="middle">TGC GGC CGC TCA TGG TCT TTT TCT T</td>
<td align="left" valign="middle">Downstream primer for PCR products (2)(5)</td></tr>
<tr>
<td align="left" valign="middle">P3UP</td>
<td align="left" valign="middle">AAA AAG ACC ATG AGC GGC CGC ATA ATG</td>
<td align="left" valign="middle">Upstream primer for PCR products (6)(8)</td></tr>
<tr>
<td align="left" valign="middle">P3DN</td>
<td align="left" valign="middle">CGT GTT TGT GCA TCC ATA TGT ATA TCT CCT T</td>
<td align="left" valign="middle">Downstream primer for PCR product (6)</td></tr>
<tr>
<td align="left" valign="middle">P4UP</td>
<td align="left" valign="middle">GAT ATA CAT ATG GAT GCA CAA ACA CGC</td>
<td align="left" valign="middle">Upstream primer for PCR products (3)(7)</td></tr>
<tr>
<td align="left" valign="middle">P4DN</td>
<td align="left" valign="middle">TGC CGT TCT TGC TAC CAG AAC C</td>
<td align="left" valign="middle">Downstream primer PCR product (3)</td></tr>
<tr>
<td align="left" valign="middle">P5UP</td>
<td align="left" valign="middle">TTC TGG TAG CAA GAA CGG CAT CAA G</td>
<td align="left" valign="middle">Upstream primer for PCR product (4)</td></tr>
<tr>
<td align="left" valign="middle">P5DN</td>
<td align="left" valign="middle">TCA AGC CTA GGT TAC TTG TAC AGC TC</td>
<td align="left" valign="middle">Downstream primer for PCR products (4)(7)(8)(9)</td></tr>
<tr>
<td align="left" valign="middle">AptUP</td>
<td align="left" valign="middle">CAC CAG GCC ACG AG T CTA GA</td>
<td align="left" valign="middle">Upstream primer for PCR of the aptamer gene</td></tr>
<tr>
<td align="left" valign="middle">AptDN</td>
<td align="left" valign="middle">GCC TGC TGC TCG TCC CTA GG</td>
<td align="left" valign="middle">Downstream primer for PCR of the aptamer gene</td></tr></tbody></table></table-wrap></app></app-group>
<ref-list>
<title>References</title>
<ref id="b1-pharmaceuticals-04-00494"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valencia-Burton</surname><given-names>M.</given-names></name><name><surname>McCullough</surname><given-names>R.M.</given-names></name><name><surname>Cantor</surname><given-names>C.R.</given-names></name><name><surname>Broude</surname><given-names>N.E.</given-names></name></person-group><article-title>RNA visualization in live bacterial cells using fluorescent protein complementation</article-title><source>Nat. Methods</source><year>2007</year><volume>4</volume><fpage>421</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">17401371</pub-id></citation></ref>
<ref id="b2-pharmaceuticals-04-00494"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valencia-Burton</surname><given-names>M.</given-names></name><name><surname>Broude</surname><given-names>N.E.</given-names></name></person-group><article-title>Visualization of RNA using fluorescence complementation triggered by aptamer-protein interactions (RFAP) in live bacterial cells</article-title><source>Curr. Protoc. Cell Biol.</source><year>2007</year><pub-id pub-id-type="doi">10.1002/0471143030.cb1711s37</pub-id></citation></ref>
<ref id="b3-pharmaceuticals-04-00494"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valencia-Burton</surname><given-names>M.</given-names></name><name><surname>Shah</surname><given-names>A.</given-names></name><name><surname>Sutin</surname><given-names>J.</given-names></name><name><surname>Borogovac</surname><given-names>A.</given-names></name><name><surname>McCullough</surname><given-names>R.M.</given-names></name><name><surname>Cantor</surname><given-names>C.R.</given-names></name><name><surname>Meller</surname><given-names>A.</given-names></name><name><surname>Broude</surname><given-names>N.E.</given-names></name></person-group><article-title>Spatiotemporal patterns and transcription kinetics of induced RNA in single bacterial cells</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>16399</fpage><lpage>16401</lpage><pub-id pub-id-type="doi">10.1073/pnas.0907495106</pub-id><pub-id pub-id-type="pmid">19805311</pub-id></citation></ref>
<ref id="b4-pharmaceuticals-04-00494"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>S.</given-names></name></person-group><article-title>Imaging intracellular RNA distribution and dynamics in living cells</article-title><source>Nat. Methods</source><year>2007</year><volume>6</volume><fpage>331</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/nmat1899</pub-id></citation></ref>
<ref id="b5-pharmaceuticals-04-00494"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darzacq</surname><given-names>X.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Larson</surname><given-names>D.R.</given-names></name><name><surname>Causse</surname><given-names>S.Z.</given-names></name><name><surname>Bosanac</surname><given-names>L.</given-names></name><name><surname>de Turris</surname><given-names>V.</given-names></name><name><surname>Ruda</surname><given-names>V.M.</given-names></name><name><surname>Lionnet</surname><given-names>T.</given-names></name><name><surname>Zenklusen</surname><given-names>D.</given-names></name><name><surname>Guglielmi</surname><given-names>B.</given-names></name><name><surname>Tjian</surname><given-names>R.</given-names></name><name><surname>Singer</surname><given-names>R.H.</given-names></name></person-group><article-title>Imaging transcription in living cells</article-title><source>Annu. Rev. Biophys.</source><year>2009</year><volume>38</volume><fpage>173</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1146/annurev.biophys.050708.133728</pub-id><pub-id pub-id-type="pmid">19416065</pub-id></citation></ref>
<ref id="b6-pharmaceuticals-04-00494"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Daigle</surname><given-names>N.</given-names></name><name><surname>Ellenberg</surname><given-names>J.</given-names></name></person-group><article-title>Lambda N-GFP: An RNA reporter system for live-cell imaging</article-title><source>Nat. Methods</source><year>2007</year><volume>4</volume><fpage>633</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1038/nmeth1065</pub-id><pub-id pub-id-type="pmid">17603490</pub-id></citation></ref>
<ref id="b7-pharmaceuticals-04-00494"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>S.</given-names></name><name><surname>Katayama</surname><given-names>Y.</given-names></name><name><surname>Schmid</surname><given-names>M.</given-names></name><name><surname>Burkacky</surname><given-names>O.</given-names></name><name><surname>Bräuchle</surname><given-names>C.</given-names></name><name><surname>Lamb</surname><given-names>D.C.</given-names></name><name><surname>Jansen</surname><given-names>R.P.</given-names></name></person-group><article-title>Simultaneous transport of different localized mRNA species revealed by live-cell imaging</article-title><source>Traffic</source><year>2008</year><volume>9</volume><fpage>1256</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2008.00763.x</pub-id><pub-id pub-id-type="pmid">18485054</pub-id></citation></ref>
<ref id="b8-pharmaceuticals-04-00494"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Remy</surname><given-names>I.</given-names></name><name><surname>Michnick</surname><given-names>S.W.</given-names></name></person-group><article-title>Application of protein-fragment complementation assays in cell biology</article-title><source>Biotechniques</source><year>2007</year><volume>42</volume><fpage>137</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.2144/000112396</pub-id><pub-id pub-id-type="pmid">17373475</pub-id></citation></ref>
<ref id="b9-pharmaceuticals-04-00494"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kerppola</surname><given-names>T.K.</given-names></name></person-group><article-title>Bimolecular fluorescence complementation (BiFC) analysis as a probe of protein interactions in living cells</article-title><source>Annu. Rev. Biophys.</source><year>2008</year><volume>37</volume><fpage>465</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1146/annurev.biophys.37.032807.125842</pub-id><pub-id pub-id-type="pmid">18573091</pub-id></citation></ref>
<ref id="b10-pharmaceuticals-04-00494"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stains</surname><given-names>C.I.</given-names></name><name><surname>Porter</surname><given-names>J.R.</given-names></name><name><surname>Ooi</surname><given-names>A.T.</given-names></name><name><surname>Segal</surname><given-names>D.J.</given-names></name><name><surname>Ghosh</surname><given-names>I.</given-names></name></person-group><article-title>DNA sequence-enabled reassembly of the green fluorescent protein</article-title><source>J. Am. Chem. Soc.</source><year>2005</year><volume>127</volume><fpage>10782</fpage><lpage>10783</lpage><pub-id pub-id-type="doi">10.1021/ja051969w</pub-id><pub-id pub-id-type="pmid">16076155</pub-id></citation></ref>
<ref id="b11-pharmaceuticals-04-00494"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>A.T.</given-names></name><name><surname>Stains</surname><given-names>C.I.</given-names></name><name><surname>Ghosh</surname><given-names>I.</given-names></name><name><surname>Segal</surname><given-names>D.J.</given-names></name></person-group><article-title>Sequence-enabled reassembly of beta-lactamase (SEER-LAC): a sensitive method for the detection of double-stranded DNA</article-title><source>Biochemistry</source><year>2006</year><volume>45</volume><fpage>3620</fpage><lpage>3625</lpage><pub-id pub-id-type="doi">10.1021/bi0517032</pub-id><pub-id pub-id-type="pmid">16533044</pub-id></citation></ref>
<ref id="b12-pharmaceuticals-04-00494"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demidov</surname><given-names>V.V.</given-names></name><name><surname>Dokholyan</surname><given-names>N.V.</given-names></name><name><surname>Witte-Hoffmann</surname><given-names>C.</given-names></name><name><surname>Chalasani</surname><given-names>P.</given-names></name><name><surname>Yiu</surname><given-names>H.W.</given-names></name><name><surname>Ding</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Cantor</surname><given-names>C.R.</given-names></name><name><surname>Broude</surname><given-names>N.E.</given-names></name></person-group><article-title>Fast complementation of split fluorescent protein triggered by DNA hybridization</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>2052</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.1073/pnas.0511078103</pub-id><pub-id pub-id-type="pmid">16461889</pub-id></citation></ref>
<ref id="b13-pharmaceuticals-04-00494"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demidov</surname><given-names>V.V.</given-names></name><name><surname>Broude</surname><given-names>N.E.</given-names></name></person-group><article-title>Profluorescent protein fragments for fast bimolecular fluorescence complementation <italic>in vitro</italic></article-title><source>Nat. Protoc.</source><year>2006</year><volume>1</volume><fpage>714</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.114</pub-id><pub-id pub-id-type="pmid">17406301</pub-id></citation></ref>
<ref id="b14-pharmaceuticals-04-00494"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rackham</surname><given-names>O.</given-names></name><name><surname>Brown</surname><given-names>C.M.</given-names></name></person-group><article-title>Visualization of RNA-protein interactions in living cells: FMRP and IMP1 interact on mRNAs</article-title><source>EMBO J.</source><year>2004</year><volume>23</volume><fpage>3346</fpage><lpage>3355</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600341</pub-id><pub-id pub-id-type="pmid">15282548</pub-id></citation></ref>
<ref id="b15-pharmaceuticals-04-00494"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C.A.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Frankel</surname><given-names>A.D.</given-names></name></person-group><article-title>Using peptides as models of RNA-protein interactions</article-title><source>Meth. Enzymol.</source><year>2000</year><volume>318</volume><fpage>423</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">10890003</pub-id></citation></ref>
<ref id="b16-pharmaceuticals-04-00494"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bayer</surname><given-names>T.S.</given-names></name><name><surname>Booth</surname><given-names>L.N.</given-names></name><name><surname>Knudsen</surname><given-names>S.M.</given-names></name><name><surname>Ellington</surname><given-names>A.D.</given-names></name></person-group><article-title>Arginine-rich motifs present multiple interfaces for specific binding by RNA</article-title><source>RNA</source><year>2005</year><volume>11</volume><fpage>1848</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1261/rna.2167605</pub-id><pub-id pub-id-type="pmid">16314457</pub-id></citation></ref>
<ref id="b17-pharmaceuticals-04-00494"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C.A.</given-names></name><name><surname>Calabro</surname><given-names>V.</given-names></name><name><surname>Frankel</surname><given-names>A.D.</given-names></name></person-group><article-title>An RNA-binding chameleon</article-title><source>Mol. Cell</source><year>2000</year><volume>6</volume><fpage>1067</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)00105-2</pub-id><pub-id pub-id-type="pmid">11106746</pub-id></citation></ref>
<ref id="b18-pharmaceuticals-04-00494"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baskerville</surname><given-names>S.</given-names></name><name><surname>Zapp</surname><given-names>M.</given-names></name><name><surname>Ellington</surname><given-names>A.D.</given-names></name></person-group><article-title>Anti-Rex aptamers as mimics of the Rex-binding element</article-title><source>J. Virol.</source><year>1999</year><volume>73</volume><fpage>4962</fpage><lpage>4971</lpage><pub-id pub-id-type="pmid">10233958</pub-id></citation></ref>
<ref id="b19-pharmaceuticals-04-00494"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X.</given-names></name><name><surname>Gorin</surname><given-names>A.</given-names></name><name><surname>Ellington</surname><given-names>A.D.</given-names></name><name><surname>Patel</surname><given-names>D.J.</given-names></name></person-group><article-title>Deep penetration of an alpha-helix into a widened RNA major groove in the HIV-1 rev peptide-RNA aptamer complex</article-title><source>Nat. Struct. Biol.</source><year>1996</year><volume>3</volume><fpage>1026</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1038/nsb1296-1026</pub-id><pub-id pub-id-type="pmid">8946856</pub-id></citation></ref>
<ref id="b20-pharmaceuticals-04-00494"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baron-Benhamou</surname><given-names>J.</given-names></name><name><surname>Gehring</surname><given-names>N.H.</given-names></name><name><surname>Kulozik</surname><given-names>A.E.</given-names></name><name><surname>Hentze</surname><given-names>M.W.</given-names></name></person-group><article-title>Using the lambda N peptide to tether proteins to RNAs</article-title><source>Methods Mol. Biol.</source><year>2004</year><volume>257</volume><fpage>135</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">14770003</pub-id></citation></ref>
<ref id="b21-pharmaceuticals-04-00494"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsushima</surname><given-names>N.</given-names></name><name><surname>Yoshida</surname><given-names>H.</given-names></name><name><surname>Kumaki</surname><given-names>Y.</given-names></name><name><surname>Kamiya</surname><given-names>M.</given-names></name><name><surname>Tanaka</surname><given-names>T.</given-names></name><name><surname>Izumi</surname><given-names>Y.</given-names></name><name><surname>Kretsinger</surname><given-names>R.H.</given-names></name></person-group><article-title>Flexible structures and ligand interactions of tandem repeats consisting of proline, glycine, asparagine, serine, and/or threonine rich oligopeptides in proteins</article-title><source>Curr. Protein Pept. Sci.</source><year>2008</year><volume>9</volume><fpage>591</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.2174/138920308786733886</pub-id><pub-id pub-id-type="pmid">19075749</pub-id></citation></ref>
<ref id="b22-pharmaceuticals-04-00494"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trinh</surname><given-names>R.</given-names></name><name><surname>Gurbaxani</surname><given-names>B.</given-names></name><name><surname>Morrison</surname><given-names>S.L.</given-names></name><name><surname>Seyfzadeh</surname><given-names>M.</given-names></name></person-group><article-title>Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression</article-title><source>Mol. Immunol.</source><year>2004</year><volume>40</volume><fpage>717</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2003.08.006</pub-id><pub-id pub-id-type="pmid">14644097</pub-id></citation></ref></ref-list></back></article>
